drugset / Trial / NCT03007875
High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer
Phase 1/2
Completed
20 enrolled
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of non-small cell lung cancer.
Timeline
- Start
- 2016-12-01
- Primary completion
- 2017-12-01
- Completion
- 2019-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | High-activity natural killer | Cell therapy | 8e+09 cells | Intravenous |
| Subject | High-activity natural killer | Cell therapy | 1e+10 cells | Intravenous |